Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

This can be an important add-on to echocardiography in patients with a borderline need for intervention, researchers say.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

The multidisciplinary care required to treat these complex patients is most often found in higher-volume centers.

Approximately one in four patients died, deteriorated to a higher shock stage, or were transferred for a higher level of care ...

Individuals assigned male at birth who were pushed to change their identity had more inflammation and higher blood pressure.

Telling patients how many extra days they’ll be free from an event can help with shared decision-making, experts say.

The novel CETP inhibitor, once tested for the now-defunct pathway of HDL raising, reduces LDL as well as Lp(a).

By group, procedural success and freedom from LVOT obstruction (LVOT mean gradient > 50 mm Hg), the primary efficacy endpoint ...

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

The tool is less apt to overestimate ASCVD risk than the pooled cohort equations and in turn could reduce overtreatment.